Oculis Holding AG
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
/ 
Frequently asked questions
To buy Oculis Holding AG stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Oculis Holding AG by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Oculis Holding AG is OCS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Oculis Holding AG has its primary listing on NASDAQ (Small cap). You can trade Oculis Holding AG with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Oculis Holding AG is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Oculis Holding AG as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Oculis Holding AG.